Bayer Invests C$1.5 Million in Canadian Coronavirus Research
21 Abril 2020 - 10:30AM
Dow Jones News
By Jessica Sier
Bayer AG said Tuesday that its Canadian arm will invest and
partner with a research institute in the country to identify
treatments against the new coronavirus.
The German chemical company will invest 1.5 million Canadian
dollars ($1.1 million) into the program, run in conjunction with
the Population Health Research Institute.
The institute has provided C$0.5 million.
The program aims to research the safety and efficacy of
different combination therapies including Bayer's chloroquine and
interferon beta-1b, the company said in a statement.
"Treatments against coronavirus are urgently needed as no
validated options are currently available," Dr. Mike Devoy of the
executive committee of Bayer's pharmaceuticals division and chief
medical officer, said.
"We want to contribute to the global fight against the
coronavirus through our products and expertise and look forward to
partnering with the PHRI."
The research institute aims to enroll 6,000 patients into the
two studies from more than 60 other research sites.
Write to Jessica Sier at jessica.sier@wsj.com
(END) Dow Jones Newswires
April 21, 2020 09:15 ET (13:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024